Zacks Investment Research Upgrades Indivior Plc Spon (INVVY) to Hold
Indivior Plc Spon (NASDAQ:INVVY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday.
According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “
Shares of Indivior Plc Spon (NASDAQ INVVY) traded down 0.57% during mid-day trading on Friday, reaching $26.30. The company had a trading volume of 1,315 shares. Indivior Plc Spon has a 52-week low of $17.18 and a 52-week high of $26.53. The company has a market capitalization of $3.79 billion and a PE ratio of 47.39. The company’s 50-day moving average price is $22.17 and its 200-day moving average price is $21.16.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Indivior Plc Spon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior Plc Spon and related companies with MarketBeat.com's FREE daily email newsletter.